Cargando…
Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139963/ https://www.ncbi.nlm.nih.gov/pubmed/35626272 http://dx.doi.org/10.3390/diagnostics12051116 |
_version_ | 1784714983432519680 |
---|---|
author | Vercellino, Laetitia de Jong, Dorine Dercle, Laurent Hosten, Benoit Braumuller, Brian Das, Jeeban Paul Deng, Aileen Moya-Plana, Antoine A’Keen, Camry Yeh, Randy Merlet, Pascal Baroudjian, Barouyr Salvatore, Mary M. Capaccione, Kathleen M. |
author_facet | Vercellino, Laetitia de Jong, Dorine Dercle, Laurent Hosten, Benoit Braumuller, Brian Das, Jeeban Paul Deng, Aileen Moya-Plana, Antoine A’Keen, Camry Yeh, Randy Merlet, Pascal Baroudjian, Barouyr Salvatore, Mary M. Capaccione, Kathleen M. |
author_sort | Vercellino, Laetitia |
collection | PubMed |
description | Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can identify molecular pathways that promote disease progression and therefore offer physiological information. Thus, they can be used to assess prognosis, tumor heterogeneity, and identify instances of treatment failure. Numerous agents tested preclinically and clinically demonstrate promising results with high tumor-to-background ratios in both primary and metastatic melanoma tumors. Here, we detail the development and testing of multiple molecular targeted PET-imaging agents, including agents for general oncological imaging and those specifically for PET imaging of melanoma. Of the numerous radiopharmaceuticals evaluated for this purpose, several have made it to clinical trials and showed promising results. Ultimately, these agents may become the standard of care for melanoma imaging if they are able to demonstrate micrometastatic disease and thus provide more accurate information for staging. Furthermore, these agents provide a more accurate way to monitor response to therapy. Patients will be able to receive treatment based on tumor uptake characteristics and may be able to be treated earlier for lesions that with traditional imaging would be subclinical, overall leading to improved outcomes for patients. |
format | Online Article Text |
id | pubmed-9139963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91399632022-05-28 Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma Vercellino, Laetitia de Jong, Dorine Dercle, Laurent Hosten, Benoit Braumuller, Brian Das, Jeeban Paul Deng, Aileen Moya-Plana, Antoine A’Keen, Camry Yeh, Randy Merlet, Pascal Baroudjian, Barouyr Salvatore, Mary M. Capaccione, Kathleen M. Diagnostics (Basel) Review Melanoma is a deadly disease that often exhibits relentless progression and can have both early and late metastases. Recent advances in immunotherapy and targeted therapy have dramatically increased patient survival for patients with melanoma. Similar advances in molecular targeted PET imaging can identify molecular pathways that promote disease progression and therefore offer physiological information. Thus, they can be used to assess prognosis, tumor heterogeneity, and identify instances of treatment failure. Numerous agents tested preclinically and clinically demonstrate promising results with high tumor-to-background ratios in both primary and metastatic melanoma tumors. Here, we detail the development and testing of multiple molecular targeted PET-imaging agents, including agents for general oncological imaging and those specifically for PET imaging of melanoma. Of the numerous radiopharmaceuticals evaluated for this purpose, several have made it to clinical trials and showed promising results. Ultimately, these agents may become the standard of care for melanoma imaging if they are able to demonstrate micrometastatic disease and thus provide more accurate information for staging. Furthermore, these agents provide a more accurate way to monitor response to therapy. Patients will be able to receive treatment based on tumor uptake characteristics and may be able to be treated earlier for lesions that with traditional imaging would be subclinical, overall leading to improved outcomes for patients. MDPI 2022-04-29 /pmc/articles/PMC9139963/ /pubmed/35626272 http://dx.doi.org/10.3390/diagnostics12051116 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vercellino, Laetitia de Jong, Dorine Dercle, Laurent Hosten, Benoit Braumuller, Brian Das, Jeeban Paul Deng, Aileen Moya-Plana, Antoine A’Keen, Camry Yeh, Randy Merlet, Pascal Baroudjian, Barouyr Salvatore, Mary M. Capaccione, Kathleen M. Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title | Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title_full | Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title_fullStr | Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title_full_unstemmed | Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title_short | Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma |
title_sort | translating molecules into imaging—the development of new pet tracers for patients with melanoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139963/ https://www.ncbi.nlm.nih.gov/pubmed/35626272 http://dx.doi.org/10.3390/diagnostics12051116 |
work_keys_str_mv | AT vercellinolaetitia translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT dejongdorine translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT derclelaurent translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT hostenbenoit translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT braumullerbrian translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT dasjeebanpaul translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT dengaileen translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT moyaplanaantoine translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT akeencamry translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT yehrandy translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT merletpascal translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT baroudjianbarouyr translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT salvatoremarym translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma AT capaccionekathleenm translatingmoleculesintoimagingthedevelopmentofnewpettracersforpatientswithmelanoma |